Orgenesis Inc (ORGS)
0.5149
+0.03
(+5.95%)
USD |
NASDAQ |
May 31, 16:00
0.4975
-0.02
(-3.38%)
After-Hours: 20:00
Orgenesis Enterprise Value: 43.83M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 43.83M |
| May 30, 2024 | 42.83M |
| May 29, 2024 | 43.31M |
| May 28, 2024 | 41.94M |
| May 24, 2024 | 42.62M |
| May 23, 2024 | 42.79M |
| May 22, 2024 | 42.62M |
| May 21, 2024 | 43.65M |
| May 20, 2024 | 45.04M |
| May 17, 2024 | 45.07M |
| May 16, 2024 | 44.35M |
| May 15, 2024 | 45.54M |
| May 14, 2024 | 46.88M |
| May 13, 2024 | 47.03M |
| May 10, 2024 | 46.03M |
| May 09, 2024 | 45.14M |
| May 08, 2024 | 43.97M |
| May 07, 2024 | 44.32M |
| May 06, 2024 | 43.97M |
| May 03, 2024 | 44.21M |
| May 02, 2024 | 44.76M |
| May 01, 2024 | 44.16M |
| April 30, 2024 | 43.47M |
| April 29, 2024 | 43.28M |
| April 26, 2024 | 43.52M |
| Date | Value |
|---|---|
| April 25, 2024 | 43.42M |
| April 24, 2024 | 43.35M |
| April 23, 2024 | 43.93M |
| April 22, 2024 | 43.52M |
| April 19, 2024 | 43.29M |
| April 18, 2024 | 43.67M |
| April 17, 2024 | 43.56M |
| April 16, 2024 | 43.26M |
| April 15, 2024 | 43.25M |
| April 12, 2024 | 43.02M |
| April 11, 2024 | 45.31M |
| April 10, 2024 | 44.08M |
| April 09, 2024 | 42.74M |
| April 08, 2024 | 42.40M |
| April 05, 2024 | 43.90M |
| April 04, 2024 | 46.01M |
| April 03, 2024 | 43.09M |
| April 02, 2024 | 39.37M |
| April 01, 2024 | 46.04M |
| March 31, 2024 | 54.32M |
| March 28, 2024 | 49.52M |
| March 27, 2024 | 50.48M |
| March 26, 2024 | 50.51M |
| March 25, 2024 | 52.15M |
| March 22, 2024 | 52.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-29.66M
Minimum
Apr 01 2020
162.08M
Maximum
Mar 12 2021
68.52M
Average
67.57M
Median
Enterprise Value Benchmarks
| Altimmune Inc | 350.45M |
| Verastem Inc | 52.61M |
| Oragenics Inc | 8.699M |
| Actinium Pharmaceuticals Inc | 158.68M |
| Dare Bioscience Inc | 38.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.765M |
| Revenue (Quarterly) | 0.141M |
| Total Expenses (Quarterly) | 9.071M |
| EPS Diluted (Quarterly) | -0.29 |
| Gross Profit Margin (Quarterly) | -248.9% |
| Profit Margin (Quarterly) | -6.93K% |
| Earnings Yield | -268.0% |
| Normalized Earnings Yield | -232.91 |